Zydus Lifesciences to launch cancer-risk tests in India

Zydus Lifesciences Limited announced an exclusive agreement with US-based Myriad Genetics to launch cancer-risk assessment diagnostic tests in India. This collaboration will introduce MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus, and Prolaris® Prostate Cancer Prognostic Test to Indian patients, clinicians, and healthcare systems. The initiative aims to provide personalised, evidence-based cancer care solutions and empower oncologists with genomic decision-support tools.

The MyRisk® Test assesses 63 clinically significant genes to estimate lifetime cancer risk, while the MyChoice® HRD Plus Test determines HRD status for advanced ovarian cancer, guiding targeted therapies. The Prolaris® Test quantifies tumor aggressiveness in prostate cancer, aiding treatment decisions. These tests, widely adopted in North America and Europe, are expected to enhance diagnostic infrastructure and clinician education in India.